June 2026 in Cardiology: TAVI's Decade Mark, a New CKM Guideline, and a Gene-Editing First
A synthesis of the month's highest-yield structural, preventive, and antiplatelet news for practicing cardiologists and physician-investors.
Overview
June is traditionally a quieter month on the conference calendar than May, yet the past four weeks produced an unusually dense cluster of practice-relevant data.
Roughly half of the most-read stories from the period trace back to New York Valves 2026, where transcatheter aortic valve implantation (TAVI) durability, futility, and reimbursement all took center stage.
Beyond the valve world, a first-ever cardiovascular-kidney-metabolic (CKM) syndrome guideline, an early but genuinely novel gene-editing therapy for LDL lowering, a practice-shaping antiplatelet meta-analysis, and a small but intriguing vitamin K trial rounded out the list.
This roundup pulls the clinical threads together and flags where physician-investors may want to keep an eye on the corporate side of the story.
TAVI at 10 Years: Reassuring, With Caveats
Two analyses published in the June 16, 2026 issue of JACC gave cardiologists their longest look yet at TAVI versus surgical aortic valve replacement (SAVR).
In the overall 10-year cohort, all-cause mortality was numerically higher after TAVI than SAVR (86.1% vs 82.8%; HR 1.13), a difference attributed largely to the older, higher-risk population that received TAVI in earlier device generations.
Notably, a propensity-matched comparison restricted to the third-generation Sapien 3 valve (Edwards Lifesciences) against contemporary SAVR patients from PARTNER 2A did not show this gap, suggesting that modern valve design and CT-based procedural planning have narrowed the durability question considerably.
Follow-up completeness remains an important limitation, since only about 62% of TAVI patients and 54% of SAVR patients had directly reported 10-year data before a supplemental vital-status sweep filled in the rest.
Extending TAVI to Asymptomatic Disease
The most closely watched update at New York Valves 2026 was the 5-year analysis of the EARLY TAVR trial, which randomized patients with asymptomatic severe aortic stenosis to prompt transfemoral TAVI or clinical surveillance.
Death and stroke curves were essentially identical between arms through the first 2 years, reinforcing the trial's original conclusion that early intervention carries no early safety penalty.
That evidence base is already reshaping coverage policy: the Centers for Medicare & Medicaid Services (CMS) has proposed expanding national TAVI coverage to asymptomatic patients, with a final ruling expected in September 2026.
The proposed decision memo would also allow triaging by chart review and give heart teams greater flexibility in documenting shared decision-making, a change that has direct workflow implications for structural programs.
This coverage expansion follows a May 2025 FDA approval of an expanded Sapien 3 indication for asymptomatic disease, a request originally submitted by Edwards Lifesciences as the EARLY TAVR trial sponsor.
Durability Through 7 Years in Low-Risk Patients
A separate late-breaking session paired new randomized and real-world data showing TAVI durability out to 7 years in low-surgical-risk patients treated with balloon-expandable valves.
Investigators described the findings as reassuring for current practice, while cautioning that even longer follow-up is still needed before extending TAVI further down the age and risk spectrum.
Complementary presentations covered the self-expanding Evolut platform (Medtronic) and small-annulus outcomes with the Navitor valve (Abbott), broadening the durability picture beyond a single device family.
Weighing Futility After a "Successful" TAVI
Not every headline was reassuring: new registry data from TRITAVI found that roughly 1 in 25 patients died between 30 days and 12 months after an otherwise uncomplicated TAVI.
Most of these deaths were noncardiovascular, and COPD, atrial fibrillation, severe chronic kidney disease, and reduced ejection fraction were the strongest independent predictors.
Investigators framed the finding as a useful, if sobering, data point for shared decision-making conversations about futility rather than a reason to withhold treatment broadly.
TAVI Headlines at a Glance
| Story | Key Metric | Practice Signal |
|---|---|---|
| 10-year TAVI vs SAVR | 86.1% vs 82.8% mortality (HR 1.13) | Gap narrows with modern Sapien 3-era practice |
| EARLY TAVR, 5-year | Equivalent death/stroke at 2 years | Supports earlier intervention in asymptomatic AS |
| 7-year durability, low risk | Reassuring across RCT + real-world data | Longer follow-up still needed |
| TRITAVI registry | 4% die between 30 days–12 months | Informs futility, shared decision-making |
| CMS coverage proposal | Decision expected September 2026 | Would expand access, ease heart-team documentation burden |
First-Ever CKM Syndrome Guideline
Away from the valve, the AHA and ACC, together with the American Diabetes Association and American Society of Nephrology, issued the first comprehensive guideline on cardiovascular-kidney-metabolic (CKM) syndrome.
The document introduces a four-stage framework, ranging from isolated risk factors (Stage 1) to established cardiovascular disease with concurrent metabolic or kidney disease (Stage 4).
Central to the guideline is broader use of the PREVENT risk equations, which incorporate kidney and metabolic variables to estimate 10- and 30-year cardiovascular risk more precisely than legacy pooled-cohort tools.
Nearly 90% of US adults have at least one CKM risk factor, underscoring how broadly this staging system is likely to apply in routine outpatient cardiology practice.
For heart failure with mildly reduced or preserved ejection fraction, the guideline reiterates SGLT2 inhibitors as first-line therapy and supports layering GLP-1–based agents in patients with obesity, alongside consideration of nonsteroidal mineralocorticoid receptor antagonists in type 2 diabetes with chronic kidney disease.
A Gene-Editing First for PCSK9
In lipid-lowering news, interim phase I data from the Heart-2 trial showed that a single infusion of the in vivo base-editing therapy VERVE-102 reduced PCSK9 protein levels by up to 88% and LDL cholesterol by up to 62% (roughly a 78 mg/dL absolute reduction) at the highest dose.
The therapy uses a GalNAc-lipid nanoparticle carrier to deliver a base-editing complex to hepatocytes, permanently inactivating the PCSK9 gene through a single adenine-to-guanine DNA edit.
Tolerability was generally favorable, with infusion-related reactions in about 20% of patients and one serious but self-limited case of aspiration pneumonitis.
On the corporate side, Verve Therapeutics became a wholly owned subsidiary of Eli Lilly and Company in July 2025, so the former Nasdaq ticker VERV has been delisted and the PCSK9 gene-editing program now sits inside Lilly's broader cardiometabolic pipeline.
A phase II study of VERVE-102 is expected to begin enrolling later in 2026, with familial hypercholesterolemia and premature coronary disease as the initial target populations.
Prasugrel Edges Out Rivals After PCI
A new meta-analysis published in JAMA Cardiology and summarized by TCTMD found that among the three major oral P2Y12 inhibitors, prasugrel offered the best overall balance of efficacy and safety after PCI.
Compared with clopidogrel, prasugrel lowered the risk of MACE, myocardial infarction, and stent thrombosis without a corresponding increase in major bleeding.
Compared with ticagrelor, prasugrel again showed lower MACE, MI, and stent thrombosis, while ticagrelor carried higher rates of major bleeding and intracranial hemorrhage.
These findings echo two prior randomized trials, ISAR-REACT 5 and TUXEDO-2, both of which leaned toward a prasugrel advantage over ticagrelor in appropriately selected post-PCI patients.
Vitamin K and Coronary Calcium: An Intriguing Signal
Finally, the Dutch VitaK-CAC trial randomized 180 patients with mild coronary calcification (Agatston scores 50–400) to daily menaquinone-7 (MK-7) supplementation or placebo.
Over 2 years, CAC score progression was significantly slower in the MK-7 group, and levels of dp-ucMGP, a vitamin K-dependent protein that inhibits vascular calcification, rose less steeply in that arm.
The annualized increase in CAC score was reduced by an estimated 19 Agatston units with MK-7 treatment relative to placebo.
Experts interviewed for the coverage were careful to note that the clinical significance of a smaller CAC increase remains uncertain, and that routine MK-7 supplementation is not yet ready for prime time outside of further confirmatory trials.
Drugs, Devices, and Companies in the News
| Agent / Device | Generic / Brand | Company (Ticker) | Notes |
|---|---|---|---|
| TAVI valve | Sapien 3 (balloon-expandable) | Edwards Lifesciences (NYSE: EW) | EARLY TAVR sponsor; ~$85–95/share range, consensus Buy |
| TAVI valve | Evolut (self-expanding) | Medtronic (NYSE: MDT) | ~$80–90/share range, consensus Buy |
| Structural heart / LAAO | Watchman; MiRus valve stake | Boston Scientific (NYSE: BSX) | Shares pulled back on Watchman guidance cuts; still consensus Buy |
| VERVE-102 (gene editing) | In vivo PCSK9 base editor | Eli Lilly (NYSE: LLY) | Former Verve Therapeutics (VERV) program; VERV delisted July 2025 |
| P2Y12 inhibitor | Prasugrel (Effient), generic available | Multiple generic manufacturers | Off-patent; lowest-cost of the potent P2Y12 agents |
| P2Y12 inhibitor | Ticagrelor (Brilinta) | AstraZeneca (Nasdaq: AZN) | Twice-daily dosing; higher bleeding signal in new meta-analysis |
| Vitamin K2 supplement | Menaquinone-7 (MenaQ7) | Gnosis by Lesaffre | Privately held; over-the-counter supplement, not FDA-regulated as a drug |
A 74-year-old man with hypertension, type 2 diabetes, and stage 3 chronic kidney disease is found to have severe aortic stenosis on a surveillance echocardiogram, without exertional symptoms on careful questioning.
He asks whether he should simply be monitored until symptoms develop, as his neighbor was advised a decade ago.
Applying the 5-year EARLY TAVR data, the cardiologist explains that early transfemoral TAVI has shown no penalty in death or stroke compared with surveillance through at least 2 years, and that pending CMS coverage changes may soon remove some of the administrative barriers to earlier intervention.
At the same visit, his CKM syndrome stage is formally documented as Stage 3, prompting initiation of an SGLT2 inhibitor and calculation of his 10-year PREVENT risk score to guide further risk-factor management.
TAVI's evidence base continues to mature in two directions at once: reassuring long-term durability data at 7 and 10 years, and expanding indications into asymptomatic disease that will likely become easier to act on once CMS finalizes its coverage decision.
The new CKM syndrome guideline gives cardiologists a shared staging language with endocrinology and nephrology, anchored by the PREVENT risk equations.
VERVE-102 remains an early but genuinely novel proof of concept for one-time gene-editing therapy in lipid management, now under Eli Lilly's umbrella rather than as a standalone public company.
For routine post-PCI antiplatelet selection, the new meta-analysis adds further support for prasugrel as a first-choice potent P2Y12 inhibitor in patients without a specific contraindication.
References
- TCTMD. New 10-Year TAVI Data Generally 'Reassuring' But Highlight Challenges.
- TCTMD. AHA/ACC Release First Comprehensive Guideline on CKM Syndrome.
- TCTMD. Gene-Editing Therapy Safely Lowers PCSK9, LDL Cholesterol in Phase I: Heart-2.
- TCTMD. Meta-analysis: Prasugrel the Best P2Y12 Inhibitor After PCI?
- TCTMD. EARLY TAVR: 5-Year Data Still Support TAVI Over Surveillance in Asymptomatic AS.
- TCTMD. Following Successful TAVI, 4% Die Between 1 and 12 Months: TRITAVI.
- TCTMD. What's Going to Be Hot at New York Valves 2026.
- TCTMD. Vitamin K Supplementation May Reduce Coronary Calcification: VitaK-CAC.
- TCTMD. CMS Proposes Expanding TAVI Coverage to Asymptomatic Patients.
- American College of Cardiology. First-Ever Guideline Addresses CKM Syndrome.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.